Background: Isocitrate dehydrogenase (IDH) wild-type (wt) glioblastoma is an aggressive malignancy associated with poor clinical outcomes, marked by high heterogeneity and resistance to treatment. This study aims to investigate the prognostic significance of B7-H3 expression in IDH wt glioblastoma and its potential association with clinical outcomes, including overall survival (OS) and progression-free survival (PFS). Additionally, the relationship between B7-H3 and PD-L1 expression was explored. Methods: A retrospective cohort of 86 IDH wt glioblastoma patients, all of whom underwent surgery, radiotherapy, and temozolomide treatment, was analyzed. B7-H3 expression was quantified using an immunoreactivity score (IRS), classifying samples as low (IRS ≤ 4) or high (IRS > 4). PD-L1 expression was evaluated based on tumor and immune cell staining, with >5% positivity indicating significant expression. Results: High B7-H3 expression was significantly associated with poorer OS and PFS. Co-expression of B7-H3 and PD-L1 was prevalent, particularly among younger male patients with unifocal tumors; however, PD-L1 expression did not show a significant correlation with clinical outcomes. Conclusions: B7-H3 appears to be a promising prognostic biomarker in IDH wt glioblastoma and may serve as a target for developing combination therapies, integrating B7-H3-targeting treatments with immune checkpoint inhibitors. Further prospective studies are necessary to validate these findings and to explore potential therapeutic strategies.

Aim: In this study, we aimed to observe the prognostic significance of the pan‐immune‐inflammation value (PIV) score calculated at the time of diagnosis in patients with locally advanced rectal cancer, as well as its effect on treatment response, survival, and prognosis.Material and Method: This retrospective, single‐center observational study was designed to analyze patients with nonmetastatic (stages II–III) rectal cancer who received neoadjuvant treatment, categorized into two groups: PIV‐L (n = 67, 50%) and PIV‐H (n = 67, 50%). The median PIV score was used for cutoff determination. Survival analysis was applied. Univariate and multivariate Cox regression analyses were used to determine prognostic factors.Results: Preoperative clinical lymph node status (p = 0.011), liver metastasis (p = 0.028), carcinoembryonic antigen (CEA; p = 0.013), and cancer antigen 19.9 (CA19.9; p = 0.040) levels; pathological complete response (p = 0.035); tumor regression score (p = 0.030); postoperative lymph node status (p = 0.019); tumor deposits (p = 0.035); and budding (p = 0.043) were statistically different between the groups. The 5‐ and 10‐year overall survival (OS) rates were 77% versus 69% and 62% versus 38% in the PIV‐L and PIV‐H groups, respectively (p = 0.032). While the PIV score was prognostic for OS in univariate analysis (HR: 1.85, 95% CI: 1.04–3.31, p = 0.035), a result of insignificance was obtained in multivariate analysis (HR: 1.76, 95% CI: 0.98–3.01 p = 0.056). The 5‐ and 10‐year disease‐free survival (DFS) rates were 67% versus 54% and 56% versus 39% in the PIV‐L and PIV‐H groups, respectively, with the PIV‐H group showing a statistically significantly lower rate (p = 0.048). For DFS, the PIV score was found to be a statistically insignificant prognostic factor in univariate analysis (HR: 0.052, 95% CI: 0.99–2.86, p = 0.052) and recognized as an independent prognostic factor in multivariate analysis (HR: 1.87, 95% CI: 1.08–3.26, p = 0.026).Conclusion: A higher pretreatment PIV score was associated with poorer clinicopathological features, a worse treatment response, lower survival rates, and a poor prognosis for DFS.